Compositions for targeting receptor for advanced glycation end-products (RAGE) in a chronic inflammatory condition

Patent metadata

Field	Value
Publication number	US-11957728-B2
Application number	US-202117552491-A
Country	US
Kind code	B2
Filing date	Dec 16, 2021
Priority date	Dec 17, 2020
Publication date	Apr 16, 2024
Grant date	Apr 16, 2024

Abstract

The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises β-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.

First claim

We claim:

1. A method for inhibiting Receptor for Advanced Glycation End products (RAGE) expression in a subject with chronic inflammatory condition, comprising: (a) identifying said subject with the chronic inflammatory condition; b) administering to said subject with a composition comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w and β-amyrin palmitate (BAP).

2. The method as claimed in claim 1 , wherein the composition comprises of 20-50% w/w BDMC, 10-25% w/w demethoxycurcumin (DMC) and 30-50% w/w curcumin, with the total curcuminoids in the composition are in the range of 20-95% w/w.

3. The method as claimed in claim 1 , wherein inhibition of RAGE expression results in decreasing expression of inflammatory markers, decreasing oxidative stress, and moderating glycation levels.

4. The method as claimed in claim 1 , wherein inhibition of RAGE expression is brought about by curcuminoids and BAP, each selected from the range of 1-10 μg/mL.

5. The method as claimed in claim 1 , wherein inhibition of RAGE expression is brought about by treating with curcuminoids and BAP each selected from the range of 50 μg/kg-100 mg/kg.

6. The method as claimed in claim 3 , wherein the inflammatory marker is selected from the group consisting of TNF-α, IL-6, and IL-1β, wherein the decrease of the inflammatory marker expression is brought about by treating with curcuminoids and BAP, each selected from the group consisting of 50 μg/kg-100 mg/kg.

7. The method as claimed in claim 3 , wherein the oxidative stress is decreased in the subject by treating with curcuminoids and BAP, each selected from the range of 50 μg/kg-100 mg/kg.

8. The method as claimed in claim 3 , wherein moderating glycan levels is brought about by treating with curcuminoids and BAP, each selected from the range of 50 μg/kg-100 mg/kg.

9. The method as claimed in claim 1 , wherein chronic inflammatory condition is selected from the group consisting of type II diabetes mellitus, cardiovascular diseases Alzheimer's disease, cancer, peripheral neuropathy, sensory losses and blindness.

10. The method as claimed in claim 1 , wherein the subject is a mammal.

11. The method as claimed in claim 1 , wherein the composition further comprises of stabilizing agents, bioavailability enhancers and antioxidants, pharmaceutically or nutraceutically or cosmeceutically accepted excipients and enhancers and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies or eatables.

12. A method of treating chronic inflammatory condition in a subject, comprising: (a) identifying said subject, b) administering said subject with a composition comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w and β-amyrin palmitate (BAP).

13. The method as claimed in claim 12 , wherein the composition comprises of 20-50% w/w BDMC, 10-25% w/w demethoxycurcumin (DMC) and 30-50% w/w curcumin, with the total curcuminoids in the composition are in the range of 20-95% w/w.

14. The method as claimed in claim 12 , wherein treating chronic inflammatory condition in the subject is brought about by inhibiting RAGE expression, decreasing expression of inflammatory markers, decreasing oxidative stress, and moderating glycation levels.

15. The method as claimed in claim 14 , wherein the inhibition of RAGE is brought about by curcuminoids and BAP, each selected from the range of 1-10 μg/mL.

16. The method as claimed in claim 14 , wherein moderating RAGE expression is brought about by treating with curcuminoids and BAP, each selected from the range of 50 μg/kg-100 mg/kg.

17. The method as claimed in claim 14 , wherein the inflammatory marker is selected from the group consisting of TNF-α, IL-6, and IL-1β, wherein the decrease of the inflammatory marker expression is brought about by treating with curcuminoids and BAP, each selected from the range of 50 μg/kg to 100 mg/kg.

18. The method as claimed in claim 14 , wherein the oxidative stress is decreased in the subject by treating with curcuminoids and BAP, each selected from the range of 50 μg/kg-100 mg/kg.

19. The method as claimed in claim 14 , wherein moderating glycan levels is brought about by treating with curcuminoids and BAP, each selected from the range of 50 μg/kg-100 mg/kg.

20. The method as claimed in claim 12 , wherein chronic inflammatory condition is selected from the group consisting of type II diabetes mellitus, cardiovascular diseases Alzheimer's disease, cancer, peripheral neuropathy, sensory losses and blindness.

21. The method as claimed in claim 12 , wherein the subject is a mammal.

22. The method as claimed in claim 12 , wherein the composition further comprises of stabilizing agents, bioavailability enhancers and antioxidants, pharmaceutically or nutraceutically or cosmeceutically accepted excipients and enhancers and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies or eatables.

Assignees

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Mundkur Lakshmi
• Sami Sabinsa Group Ltd

Inventors

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Mundkur Lakshmi

Classifications

• A61K36/9066 Primary

  Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger · CPC title

• A23L33/105

  Plant extracts, their artificial duplicates or their derivatives · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0056

  Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals · CPC title

• A61K9/2009

  Inorganic compounds · CPC title